Interlid specializes in delivering comprehensive Internationalization services tailored for innovative healthcare ventures. Our mission is to empower our clients by facilitating seamless global expansion, from early-stage multi-centric clinical trials to mature-stage market entry, sales growth, and sustainable international commercialization. Key components of our Internationalization Service we offer include:
For Early-Stage / Clinical Development Phase: (i) Design and oversight of multi-centric clinical trials across multiple geographies, ensuring compliance with local regulations; (ii) Identification and recruitment of Key Opinion Leaders (KOLs) Selection and engagement of reference hospitals and clinical sites for clinical trials, or post-market studies; and (iii) Management of clinical trials abroad, including site feasibility, contracts, monitoring, ethics approvals, and operational coordination to accelerate timelines and data quality.
For Mature / Commercialization Phase: (i) Business and sales development; (ii) Building high-performance sales teams, distributor/partnership networks, and direct market entry strategies; (iii) Regulatory entry support: Navigating country-specific needs, and other regulatory aspects; (iv) Market analysis and adaptation: Tailored sizing, segmentation, competitive benchmarking, reimbursement feasibility, and stakeholder mapping per geography; (v) Business strategy planning: Customized go-to-market plans, pricing/reimbursement models, and scaling roadmaps aligned with international opportunities; (vi) Market access execution: Payer negotiations, health technology assessments (HTA), and guideline integration across regions; and (vii) Go-to-market implementation: Launch planning, KOL advocacy, sales force optimization, and performance tracking for profitable growth. Our multidisciplinary team of clinical, regulatory, market access, business development, financial, and commercial experts, delivers high-impact, integrated services that bridge clinical validation with commercial success. We foster partnerships that turn geographical diversity into competitive advantage.
The standard hourly rate range fluctuates between €150 and €250 per hour, depending on project complexity, the required level of expertise and the involved team (senior strategists, regulatory specialists, market access experts, physicians, bioethicists, and financial analysts). Nevertheless, most clients prefer our fixed-price project structures or tailored packages, which offer predictability, and which are calculated based on the objectives and estimation of work to be done, and agreed prior to the commencement of the project. EIC beneficiaries are offered a minimum 20% discount.
The information provided in this description of Interlid Healthcare SL's Internationalization services is for informational purposes only and does not constitute legal, financial, regulatory, medical, investment, clinical, or business advice. While Interlid strives to deliver accurate, high-quality, and integrated support based on our expertise in healthcare, biotechnology, medical devices, pharmaceuticals, and related fields, we make no representations or warranties of any kind, express or implied, regarding the completeness, accuracy, timeliness, reliability, feasibility, or suitability of the services, strategies, recommendations, trial setups, partnerships, or outcomes for any particular purpose. Internationalization outcomes‚ including successful multi-country clinical trial execution, KOL/reference center engagement, regulatory approvals in target markets, market entry timelines, sales growth, reimbursement achievements, partnership formations, or commercial scaling‚ depend on numerous external and unpredictable factors beyond our control, such as evolving regulatory frameworks (e.g., EMA, FDA, national authorities), local ethics committee decisions, geopolitical conditions, payer policies, competitor actions, economic fluctuations, clinical data variability, site performance, cultural/adoption barriers, and client-specific execution. Clinical trial processes, regulatory submissions, and market access pathways are inherently uncertain and subject to risks that may cause delays, failures, additional costs, or material differences from projected results. Interlid's services are tailored to innovative ventures, including EIC-funded companies, but past performance, client successes, historical partnerships, or network reach do not guarantee future results, trial approvals, market penetration, investment outcomes, or commercialization success. We strongly recommend consulting qualified independent professionals‚ such as legal counsel, regulatory experts (e.g., for specific country filings), clinical research organizations (CROs), financial advisors, and local experts in target geographies‚ for decisions involving clinical development, trial conduct, regulatory strategies, investments, market entry, sales expansion, mergers and acquisitions, or business planning. Interlid assumes no liability for any actions, decisions, losses, damages, delays, trial complications, regulatory rejections, partnership failures, financial impacts, or consequences (direct, indirect, incidental, consequential, or otherwise) taken or incurred based on our assessments, recommendations, networks, introductions, management support, or services. Users of our services agree to indemnify Interlid against any claims, demands, or liabilities arising from such use.
Internationalisation
Are you in doubt if this is the right service for you, or do you want to get more information about the service? Get in touch with the EIC Partner providing this service through this query form!
Is this the service you are looking for? If so, you can apply to the service through EIC ACCESS+! Eligible applicants can also get co-funding through the EIC ACCESS+ initiative. Find out more on the project webiste.
Receive up to €60,000 in grants, covering up to 50% of the costs, to access specialised services from the EIC Service Catalogue. Learn more on the EIC ACCESS+ website.